DexCom (DXCM) Set to Announce Earnings on Wednesday

DexCom (NASDAQ:DXCM) will be issuing its Q3 2019 quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of $0.20 per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

DexCom stock opened at $158.54 on Tuesday. The business has a 50-day simple moving average of $153.92 and a two-hundred day simple moving average of $145.07. The company has a market cap of $14.06 billion, a P/E ratio of 528.47 and a beta of 0.64. DexCom has a 52-week low of $105.05 and a 52-week high of $178.45. The company has a quick ratio of 5.64, a current ratio of 6.05 and a debt-to-equity ratio of 1.56.

Get DexCom alerts:

In related news, EVP Richard Doubleday sold 1,533 shares of the business’s stock in a transaction that occurred on Wednesday, October 23rd. The stock was sold at an average price of $152.34, for a total value of $233,537.22. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Heather S. Ace sold 7,243 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $174.80, for a total value of $1,266,076.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 94,014 shares of company stock worth $14,608,576. 1.80% of the stock is owned by insiders.

DXCM has been the subject of a number of recent research reports. UBS Group boosted their price target on DexCom from $140.00 to $160.00 and gave the company a “neutral” rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded DexCom from a “hold” rating to a “buy” rating and set a $154.00 price objective for the company in a research note on Friday, October 25th. Oppenheimer boosted their price objective on DexCom from $167.00 to $180.00 in a research note on Thursday, August 1st. JPMorgan Chase & Co. boosted their price objective on DexCom from $170.00 to $190.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Finally, Robert W. Baird boosted their price objective on DexCom from $186.00 to $195.00 and gave the company an “outperform” rating in a research note on Thursday, August 29th. Five equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. DexCom presently has a consensus rating of “Buy” and an average target price of $171.94.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

See Also: Which market index is the best?

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.